
Proposal for the Public Procurement Act, adoption of a new pharmaceutical legislation, and revision of pharmacovigilance practices should improve patient access to safe and innovative medicines in Europe.
Dr Seán McMahon explains how Ashland’s Viatel™ bioresorbable work and rationalizes why formulators should consider using in the development of long acting injectables and implants.
Ashland has launched Viatel™ ultrapure bioresorbable polymers (lactide / glycolide / caprolactone chemistries), a higher purity platform of controlled release polymers used in long acting injectables and implants (LAII). Ultrapure provides improved release consistency, extended-release durations and are better suited for sensitive drug compounds due to the less acidic micro-environment.






